bioXXmed AG (XTER:T5O) Debt-to-Asset : 0.00 (As of Jun. 2023)

View and export this data going back to 2006. Start your Free Trial

What is bioXXmed AG Debt-to-Asset?

bioXXmed AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. bioXXmed AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was €0.00 Mil. bioXXmed AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2023 was €21.34 Mil. bioXXmed AG's debt to asset for the quarter that ended in Jun. 2023 was 0.00.

bioXXmed AG Debt-to-Asset Historical Data

The historical data trend for bioXXmed AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bioXXmed AG Debt-to-Asset Chart

bioXXmed AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Asset

Get a 7-Day Free Trial

0.01

bioXXmed AG Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Asset	Get a 7-Day Free Trial															-	0.01	0.02	-	-

Competitive Comparison of bioXXmed AG's Debt-to-Asset

For the Biotechnology subindustry, bioXXmed AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bioXXmed AG's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bioXXmed AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where bioXXmed AG's Debt-to-Asset falls into.

bioXXmed AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

bioXXmed AG's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	21.608
	=	0.00

bioXXmed AG's Debt-to-Asset for the quarter that ended in Jun. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	21.338
	=	0.00

bioXXmed AG (XTER:T5O) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

bioXXmed AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of bioXXmed AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

bioXXmed AG (XTER:T5O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bioXXmed AG (XTER:T5O) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

T5O:Germany T5O:Germany

Address

Riedstrasse 2, Darmstadt, HE, DEU, 64295

Website

https://www.bioxxmed.ag

bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.

bioXXmed AG (XTER:T5O) Headlines

No Headlines